Entrada Therapeutics Appoints New Board Member

An announcement from Entrada Therapeutics Inc ( (TRDA) ) is now available.

On May 30, 2025, Entrada Therapeutics expanded its Board of Directors from six to seven members, appointing Maha Radhakrishnan, M.D., as a Class III director and a member of the Audit Committee, effective June 1, 2025. Dr. Radhakrishnan brings extensive experience in global drug development, which is expected to support Entrada’s clinical momentum, particularly in advancing its Duchenne muscular dystrophy programs. Her appointment is seen as a strategic move to enhance the company’s capability in delivering innovative therapies for serious illnesses.

The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.

Spark’s Take on TRDA Stock

According to Spark, TipRanks’ AI Analyst, TRDA is a Neutral.

Entrada Therapeutics is positioned well in the biotechnology sector with promising developments in its clinical programs, as evidenced by recent regulatory approvals. However, challenges in sustaining revenue growth and managing cash flows are notable risks. The stock’s undervalued nature provides potential upside, contingent on overcoming operational challenges and capitalizing on strategic opportunities.

To see Spark’s full report on TRDA stock, click here.

More about Entrada Therapeutics Inc

Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular sites previously considered inaccessible. The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to deliver RNA- and protein-based therapeutics for neuromuscular and ocular diseases, including Duchenne muscular dystrophy.

Average Trading Volume: 140,220

Technical Sentiment Signal: Sell

Current Market Cap: $308.9M

Find detailed analytics on TRDA stock on TipRanks’ Stock Analysis page.